World’s only brain-guided heat shock protein induction could help millions affected with neurologic disorders
AVENTURA, Fla. – BTT Corp. (btt), a medical technology company focused on the development of innovative devices and treatments for targeted heat shock protein induction, today announced that Oklahoma Rock Holdings, LLC (Oklahoma Rock) has completed an investment of $29.3 million. btt’s technology development utilizes the first and only brain-guided advanced cerebral hyperthermia system based on brain thermoregulatory frequencies and the brain thermal tunnel discovered by btt Founder and Chief Scientific Officer, M. Marc Abreu, MD.
“We are glad to expand our health care portfolio with an investment in btt. We are excited about their research into the application of their brain-focused technology on currently unmet health conditions,” said Zach Osko, managing director of Oklahoma Rock.
btt is focused on technology development for the application of the brain thermal tunnel discovery and brain thermodynamics across numerous health conditions. This includes the prevention and treatment of a wide range of neurologic disorders ranging from multiple sclerosis to Alzheimer’s disease, Parkinson’s disease, ALS, ataxia, multiple system atrophy, and Huntington’s disease.
“Our unique brain-guided ability to induce heat shock proteins has the potential to restore brain function by refolding misfolded proteins and degrading toxic aggregates. Alzheimer’s alone, for example, affects an estimated 50 million people worldwide. We believe that these people, as well as the millions of people affected by neurodegenerative disorders, may be able to benefit from our brain-based technologies,” said btt President and CEO Robert Mogel. “This investment by Oklahoma Rock will enable us to significantly expand our operations and continue to advance our research into diagnostic and therapeutic technologies.”
“Albert Einstein once said, ‘Future medicine will be the medicine of frequencies,’ and at btt, we embody this vision in our very foundation as we strive to reduce human suffering and preserve lives,” said Dr. Abreu, who is responsible for technology development. “We believe that our technology holds immense promise for preventing and treating neurologic diseases at the molecular level and we are thrilled to partner with such a respected organization as Oklahoma Rock to move this goal forward. This capital infusion will allow us to expand our team of talented doctors and engineers to delve deeper into the research for developing exciting applications made possible by the brain thermal tunnel discovery.”
About btt Corp (Brain Tunnelgenix Technologies, Corp): Headquartered in Aventura, Fla., btt Corp. is a medical technology company that is developing solutions based on the brain thermal tunnel with a broad range of applications in therapeutics, diagnostics, disease prevention, sports applications for improving performance and increasing longevity. The company is the sole licensee of proprietary products and algorithms that track and modulate brain temperature and thermodynamics in a noninvasive way using high resolution sensors and inductors. The company is harnessing the power of brain thermodynamics, thermoregulatory frequencies, and artificial intelligence to develop molecular treatments via brain-guided heat shock protein induction for refolding the misfolded proteins that cause neurologic diseases. For more information about BTT please email a request to [email protected].
About Oklahoma Rock Holdings, LLC: Oklahoma Rock Holdings, LLC is an investment vehicle controlled by Jeff Records. Jeff Records is Chairman and CEO of MidFirst Bank, the largest privately held bank in the US. Outside of banking, Jeff has played various roles as an entrepreneur, developer, and investor. He has interests in construction, hospitality, private equity, and professional sports.
About Dr. M. Marc Abreu: Dr. Abreu is a medical doctor, former faculty at Yale University School of Medicine and Harvard Medical School, who engineered and patented BTT technologies. Dr. Abreu, an expert in brain thermodynamics and thermoregulatory frequencies, was the first to delineate the radiation signature of the glucose molecule (resulting in U.S. Patent # 7403805), and he also discovered the brain temperature tunnel while at Yale University, which allowed for the first noninvasive measurement of brain temperature through a thermophysical pathway. This discovery led to his invention of the computer based, FDA-cleared Abreu BTT 700 system.
In his private practice, Dr. Abreu has treated patients with neurodegeneration including Alzheimer’s disease, Parkinson’s disease, ataxia, Huntington’s disease, motor neuron diseases (ALS), and multiple system atrophy, as well as multiple sclerosis, epilepsy, and other neurologic diseases based on modulation of brain thermodynamics, thermoregulatory frequencies.